KINEVAC Drug Patent Profile
✉ Email this page to a colleague
When do Kinevac patents expire, and when can generic versions of Kinevac launch?
Kinevac is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in KINEVAC is sincalide. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the sincalide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Kinevac
A generic version of KINEVAC was approved as sincalide by MAIA PHARMS INC on November 22nd, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for KINEVAC?
- What are the global sales for KINEVAC?
- What is Average Wholesale Price for KINEVAC?
Summary for KINEVAC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 47 |
| Clinical Trials: | 1 |
| Patent Applications: | 1,477 |
| Drug Prices: | Drug price information for KINEVAC |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for KINEVAC |
| What excipients (inactive ingredients) are in KINEVAC? | KINEVAC excipients list |
| DailyMed Link: | KINEVAC at DailyMed |
Recent Clinical Trials for KINEVAC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Temple University | N/A |
| Johns Hopkins University | N/A |
| Penn State University | N/A |
Pharmacology for KINEVAC
| Drug Class | Cholecystokinin Analog |
US Patents and Regulatory Information for KINEVAC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | KINEVAC | sincalide | POWDER;INTRAVENOUS | 017697-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for KINEVAC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bracco | KINEVAC | sincalide | POWDER;INTRAVENOUS | 017697-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Bracco | KINEVAC | sincalide | POWDER;INTRAVENOUS | 017697-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for KINEVAC
See the table below for patents covering KINEVAC around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| United Kingdom | 1278682 | ⤷ Sign Up | |
| Canada | 2503982 | FORMULATIONS A BASE DE SINCALIDE (SINCALIDE FORMULATIONS) | ⤷ Sign Up |
| Germany | 1922185 | ⤷ Sign Up | |
| Sweden | 372007 | ⤷ Sign Up | |
| Australia | 2003304382 | Sincalide formulations | ⤷ Sign Up |
| Denmark | 132074 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
